Evolus (EOLS) Change in Accured Expenses (2017 - 2026)
Evolus (EOLS) reported Change in Accured Expenses of -$3.7 million for Q1 2026, up 73.58% on a YoY basis from -$2.2 million in Q1 2025, and down 194.69% quarter-over-quarter from $4.0 million in Q4 2025.
Evolus (EOLS) Change in Accured Expenses (2017 - 2026) Analysis & Trends
Evolus has reported Change in Accured Expenses for 10 years, with the latest figure at -$3.7 million in Q1 2026.
- For the quarter ending Q1 2026, Change in Accured Expenses rose 73.58% year-over-year to -$3.7 million; the trailing twelve-month figure through Mar 2026 stood at $4.1 million (up 141.9% YoY), and the FY2025 full-year result was -$6.4 million, down 191.2% from the prior year.
- Change in Accured Expenses for Q1 2026 stood at -$3.7 million, down from $4.0 million in the prior quarter.
- The five-year high for Change in Accured Expenses was $7.9 million in Q2 2024, with the low at -$14.2 million in Q1 2025.
- Historically, Change in Accured Expenses has averaged $40588.2 across 5 years, with a median of $2.1 million in 2023.
- Annual changes were most pronounced in 2022 — Change in Accured Expenses plunged 355.53% — and 2024, when it surged 278.36%.
- Evolus' Change in Accured Expenses stood at -$5.1 million in 2022, then soared by 239.52% to $7.1 million in 2023, then decreased by 17.73% to $5.8 million in 2024, then plunged by 32.31% to $4.0 million in 2025, then tumbled by 194.69% to -$3.7 million in 2026.
- The last three Change in Accured Expenses figures came in at -$3.7 million (Q1 2026), $4.0 million (Q4 2025), and $2.5 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | -144.00 Mn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | -234.00 Mn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | -12.70 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | -14.30 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | - |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 4.89 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | 10.02 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 23.00 Mn |
| 10 | Evolus | 437.40 Mn | 387.61 Mn | 48.90 Mn | -3.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.74 Mn |
| Mar 31, 2026 | -3.74 Mn |
| Dec 31, 2025 | 3.95 Mn |
| Dec 31, 2025 | 3.95 Mn |
| Sep 30, 2025 | 2.52 Mn |
| Sep 30, 2025 | 2.52 Mn |
| Jun 30, 2025 | 1.34 Mn |
| Jun 30, 2025 | 1.34 Mn |
| Mar 31, 2025 | -14.17 Mn |
| Mar 31, 2025 | -14.17 Mn |
| Dec 31, 2024 | 5.84 Mn |
| Dec 31, 2024 | 5.84 Mn |
| Sep 30, 2024 | 2.16 Mn |
| Sep 30, 2024 | 2.16 Mn |
| Jun 30, 2024 | 7.85 Mn |
| Jun 30, 2024 | 7.85 Mn |
| Mar 31, 2024 | -8.87 Mn |
| Mar 31, 2024 | -8.87 Mn |
| Dec 31, 2023 | 7.10 Mn |
| Dec 31, 2023 | 7.10 Mn |